Introduction {#s0005}
============

Striae gravidarum (SG) is a common, disfiguring, gestational change that affects between 55% ([@bb0040], [@bb0220]) and 90% ([@bb0090]) of women ([@bb0105], [@bb0245]). SG presents as atrophic linear scars and can cause distress, often leading to a decrease in quality of life ([@bb0135], [@bb0215]). SG are often overlooked as a cosmetic concern, which does not make the patient burden any less. Current research on risk factors, prevention, and management of this condition has been limited or met with little success and/or provided conflicting results ([@bb0040]).

Throughout history, stretch marks have always been a source of distress for pregnant women. As early as 16 BC, the poet Ovid alluded to women who would self-abort their pregnancies to avoid stretch marks ([@bb0250]). Ancient Egyptians recorded numerous preparations for the treatment of stretch marks and Soranus and Pliny the Elder in the 1st Century AD endorsed unripe olive oil and sea salt, respectively ([@bb0210]). Frankincense is one of the most often recommended treatments ([@bb0195]). There has been an additional wide range of therapeutics from topical medications to surgical modalities proposed for stretch marks, which reinforces the concern that is associated with this condition.

SG first present as flat, pink-to-red bands (striae rubra or immature striae) that become raised, longer, wider, and violet-red ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}). Over a period of months to years, the marks fade and become hypopigmented (striae alba or mature striae), appearing parallel to skin tension lines as scar-like, wrinkled, white, and atrophic marks ([Fig. 3](#f0015){ref-type="fig"}; [@bb0260], [@bb0275], [@bb0330]). SG can cause itching, burning, and discomfort and typically present on the breasts, abdomen, hips, and thighs. Up to 90% of SG appear in primigravidas ([@bb0040]). Onset has typically been reported in the late second and early third trimester; however, one study has demonstrated that 43% of women develop SG prior to 24 weeks of gestation ([@bb0040]).Fig. 1Immature striae (striae rubra) on the abdomen.Fig. 1.Fig. 2Striae rubra on the thigh.Fig. 2.Fig. 3Mature striae (striae alba) on the abdomen.Fig. 3.

The etiopathogenesis involves a combination of genetic factors ([@bb0070]), hormonal factors ([@bb0040], [@bb0050], [@bb0150], [@bb0155]), and increased mechanic stress on connective tissue ([@bb0095], [@bb0105], [@bb0155], [@bb0330]). Interestingly, skin stretch has been a controversial trigger as studies have demonstrated an inconsistent association of SG with maternal weight gain and abdominal and hip girth stretch ([@bb0025], [@bb0040], [@bb0230]). With regard to hormonal factors, twice as many estrogen receptors and elevated androgen and glucocorticoid receptors have been observed in striae compared with those in healthy skin ([@bb0050]). Pregnancy's distinct hormonal milieu is thought to influence connective tissue that is susceptible to SG when stretched. Ultimately, abnormalities in elastic fibers ([@bb0225], [@bb0265], [@bb0320]), collagen fibrils ([@bb0225], [@bb0270]), and other extracellular membrane components ([@bb0330]) are believed to underlie the pathogenesis of SG ([@bb0325]).

Histologically, the appearance of SG is similar to striae distensae (SD) and contingent on lesion age. Early on, active lesions are comprised predominantly of fine elastic fibers but aging lesions demonstrate a thinning of the dermis and decrease of collagen content in the upper dermis ([@bb0330]). Biopsy tissue samples of SG show a disorganization, shortening, and thinning of the elastic fiber network compared with tissue samples of normal skin ([@bb0155], [@bb0325]). Although they are thin and disorganized, fibrils are tropoelastin-rich, which is likely due to uncoordinated synthesis ([@bb0325]). Light microscopy demonstrates a flattening of the epidermis with atrophy and loss of rete ridges and increased glycosaminoglycans ([@bb0155], [@bb0260], [@bb0330]). However, the severity and development of lesions varies among patients, which indicates a variable genetic predisposition.

Methods {#s0010}
=======

A systematic literature search was conducted using textbooks and PubMed and MEDLINE databases to date to identify evidence-based data on the risk factors, prevention, and management of SG. Key search terms included striae gravidarum, pregnancy stretch marks, and pregnancy stretch. A literature search up to August 2016 revealed 28 articles available online that specifically studied SG, including cross-sectional, prospective, randomized controlled, and quasi-randomized controlled studies. The search was restricted to English-language articles with the exception of two articles that were translated from German. [Table 1](#t0005){ref-type="table"} provides a summary of studies that assessed risk factors of SG. [Table 2](#t0010){ref-type="table"} includes studies that assessed SG prevention methods. [Table 3](#t0015){ref-type="table"} shows studies that are relevant to SG treatments and treatment efficacy and their adverse events. In addition to the limited number of studies on the management of SG ([Table 3](#t0015){ref-type="table"}), we incorporated a review of the most current treatments in use for nongestational SD, which may be used as a guide for future SG treatment.Table 1Risk factors for striae gravidarumTable 1.Investigators and Study TypeNumber of Subjects and Subject profilesRisk Factors Identified[⁎](#tf0005){ref-type="table-fn"}Treatments[@bb0220]\
\
Cross-sectional study800 primiparous ♀ examined postpartum with mean age of 26.3▪Younger age▪Higher pre-pregnancy weight▪Body mass index▪Higher weight at delivery▪Higher gestational weight gain▪Fitzpatrick skin types I and IV▪Absence of employment▪Family history of striae gravidarumTopical treatments to reduce the occurrence of SG were not found to be effective[@bb0130]\
\
Cross-sectional study299 Caucasian ♀ up to 6 mos after delivery, without distinguishing primiparous or multiparas.▪Previous history of SG▪Family history of SG▪Higher BMI before pregnancy▪Lack of chronic diseases▪Higher birthweight▪SD on the breasts increased risk (71.4% with striae on breasts vs. 28.6% without)▪SD on thighs decreased risk (23% with striae vs. 77% without striae)Progesterone treatment was not found to be related to SG[@bb0120]\
\
Cross-sectional study280 Thai ♀ who had just given birth to first child, in the immediate postpartum period.▪Younger age (22.8 yr vs. 26.6 yr)▪Higher pre-pregnancy BMI (21.2 kg/m2 vs. 19.8 kg/m^2^)▪Higher maternal BMI at pregnancy (27.3 kg/m2 vs. 25.6 kg/m^2^)▪Higher gestational age at delivery (39.1 wk vs. 38.6 wk)▪Higher birth weight of baby (3,078.8 g vs. 2,895.8)▪Alcohol drinker (91.4% vs. 8.6%)▪Had little water intake (7.4 glasses vs. 8.3 glasses)▪Family history of SG (82.8% vs. 17.2%)Did not assess[@bb0200]\
\
Cross-sectional study112 primiparous Lebanese ♀ assessed during the immediate postpartum period▪Younger age (26.5 yr vs. 30.5)▪Increased weight gain during pregnancy (15.6 kg vs. 38.4 kg)▪Birth weight, gestational age at delivery, and family history of SG associated with moderate-to-severe SGDid not assess[@bb0025]\
\
Cross-sectional study with questionnaire309 primiparous ♀ within 48 hours of delivery▪Most significant was low maternal age▪20% (14 of 71) of teenagers had severe striae, not seen in ♀ over 30 yr of age.▪Pre-pregnancy BMI greater than 26▪Maternal weight gain of more than 15 kg▪High neonatal birth weightDid not assess[@bb0040]\
\
Cross-sectional study with anonymous survey161 ♀ who had just given birth▪Most significant was a history of breast or thigh striae (81% who developed SG had striae history vs. 31% without SG who had history of striae)▪Having a mother with SG▪Additional family history (sisters, daughters, grandmothers, aunts, cousins) of SG▪Non-white ♀ had higher association with SG (odds ratio = 4.2, 95% CI 1.9, 9.6).▪Pre-pregnancy BMI not significantly differentDid not assess[@bb0080]\
\
Prospective observational study211 singleton primiparous pregnant ♀ who were hospitalized for birth and who did not have systemic diseases or other risk factors, like drug use or polyhydramnios.▪Younger age▪Higher pre-conceptional BMI▪Family history▪Having a male baby▪Lower educational level▪Smoking status, skin type, water intake, and level of financial income did not significantly predict SGUse of preventive oil or drugs, did not affect development of SG[@bb0085]\
\
Prospective study69 primigravidas using prophylactic iron and vitamin preparations at 36 wks gestation or greater▪Family history▪Reduced blood vitamin C levels▪No significant relation with age, weight gain during pregnancy, abdominal/thigh circumference, or smoking statusDid not assess[@bb0300]\
\
Prospective observational study128 primigravid ♀ who presented in labor or for induction of labor▪Younger age▪Higher pre-delivery BMI▪Higher baby weightDid not assess[@bb0055]\
\
Prospective study76 primiparous ♀▪Younger age▪Higher weight▪Higher baby weightSG were less common in skin messaged with olive oil[@bb0160]\
\
Retrospective cohort study48 nulliparous ♀ at 34 to 36 weeks\' estimated gestational age▪Younger age▪More likely to receive state medical assistance▪More likely to have hip striae▪Greater weight gain during pregnancy▪Diabetes tests and glycosylated hemoglobin levels were similar in ♀ with and without striae.♀ who used oils or creams formed striae as frequently as those who did not[^1][^2]Table 2Prevention of striae gravidarumTable 2.Investigators and Study TypeNumber of Subjects and Subject ProfilesPreventive Methods UsedResults of Preventive Methods[⁎](#tf0010){ref-type="table-fn"}[@bb0170]\
\
Randomized, double-blind, placebo-controlled study80 pregnant ♀ during their first 12 weeks of a healthy pregnancyTrofolastin cream with *Centella asiatica* extract, α-tocopherol and collagen--elastin hydrolysates; applied daily from 12^th^ week of pregnancy until delivery▪Development of SG: 56% in placebo group vs. 34% in treatment group▪Intensity of SG was significantly lower in ♀ treated with cream vs. placebo▪In ♀ with history of striae during puberty, cream prevented SG in 89% of cases, whereas all ♀ formed SG in the placebo group[@bb0100]\
\
Randomized, double-blind, placebo-controlled study183 pregnant patients over age 18 at week 12 +/- 2Cream containing hydroxyprolisilane-C, rosehip oil, Centella asiatica triterpenes and vitamin E; applied twice a day around 12 weeks of pregnancy▪Effective in preventing SG only in ♀ without a history of striae (6% developed SG on treatment vs. 35% on placebo)▪Severity of previous stretch marks increased in the control group during the study, but not in the treated group▪Among ♀ who developed new SG, there was increased severity in control vs. treated group[@bb0290]\
\
Randomized clinical study70 nulliparous ♀ aged between 20-30 yrs old, in 18--20th week of gestation with BMI ranging between 18.5-25. 35 used treatment, 35 did notOlive oil applied topically onto abdomen twice daily, without massaging, vs. no olive oil▪SG occurred at the end of the second quarter of pregnancy in 45.7% in intervention group vs. 62.9% in control group (*p* = 0.115)▪Difference NOT statistically significant[@bb0280]\
\
Randomized controlled clinical study100 nulliparous pregnant ♀; 50 used treatment, 50 did notOlive oil applied topically onto abdomen twice daily, without massaging, vs. no olive oil▪Frequency of severe SG was lower in group that used olive oil.▪Difference NOT statistically significant[@bb0065]\
\
Randomized controlled study90 pregnant ♀; 30 received treatment cream, 30 received vitamin cream, 30 received placeboAlphastria cream (hyaluronic acid, allantoin, vitamin A, vitamin E and calcium pantothenate) vs. vitamin cream vs. placebo cream; messaged for a few minutes daily to the thighs, abdomen and chest, starting at the 3rd month of pregnancy and ending 3 mos after childbirth▪SG developed in 10% of alphastria treated group vs. 40% of vitamin treated group vs. 37% in placebo treated group[@bb0335]\
\
Randomized controlled study50 pregnant ♀; 24 received treatment, 26 did not receive any treatmentVerum cream (vitamin E, essential fatty acids, panthenol, hyaluronic acid, elastin and menthol); massaged onto the abdomen, thighs and breasts starting at the 20th week of pregnancy▪SG developed in 29% of verum treated group vs. 62% in no treatment group[@bb0285]\
\
Parallel randomized controlled clinical study150 nulliparous ♀ at their second trimester of pregnancy in Iran. 50 subjects in each groupOlive oil vs. Saj® cream that contains lanolin, stearin, triethanolamine, almond oil, and bizovax glycerin amidine vs. placebo▪SG occurred in 72% of olive oil group vs. 64% in Saj® cream group vs. 60% in control group.▪Differences NOT statistically significant[@bb0205]\
\
Randomized double-blind placebo-controlled study175 nulliparous ♀ in Lebanon with singleton pregnancies between week 12 and 18 weeks of gestation. 91 with study treatment, 84 with placeboCocoa butter lotion vs. placebo lotion, daily from weeks 12-18▪SG developed in 45% of patients using cocoa butter cream vs. 48% using placebo▪Difference NOT statistically significant[@bb0035]\
\
Randomized, double-blind, placebo-controlled study300 pregnant ♀; 150 received treatment, 150 placeboCocoa butter lotion vs. placebo lotion, daily from 16 weeks to delivery▪SG developed in 44% of patients using cocoa butter cream vs. 55% using placebo▪Difference NOT statistically significant[@bb0305]\
\
Posttest-only quasi-experimental design with a control group141 primiparous ♀ who visited the pregnancy unit in Turkey between February 1st, 2010 and April 15th, 2011. 47 subjects in oil + massage, 48 in oil -- massage, 46 in controlBitter almond oil applied with or without massage vs. control; applied every other day in weeks 19--32 of pregnancy, followed by daily until delivery▪Frequency of SG: 20% among ♀ who applied oil with massage vs. 38.8% among those who applied w/o massage vs. 41.2% in control group[@bb0230]\
\
Prospective study116 primigravidas;♀ 55 used treatment, 66 did notOlive oil vs. no olive oil applied daily▪SG developed in 68% of olive oil group vs. 55% not using olive oil.▪Difference NOT statistically significant[@bb0055]\
\
Prospective study76 primiparous ♀; 35 used treatment, 41 did notOlive oil massaged into abdomen daily vs. no olive oil▪The prophylactic use of olive oil to massage the abdomen was associated with a lower incidence of SG[^3][^4]Table 3Treatment of striae gravidarumTable 3.Investigators and Study TypeNumber of Subjects and Subject ProfilesType of StriaeTreatmentEfficacy[⁎](#tf0015){ref-type="table-fn"}Adverse Effects[@bb0165]\
\
Prospective pilot study10 ♀ aged 26-50, Fitzpatrick skin types III-VStriae alba1540-nm non-ablative fractional laser▪Clinical improvement in striae ranging from 1-24%▪Improvement between the 4-week treatment and the 16-week treatment was identified▪3 mos after final treatment, patients had observable improvement in the striae, compared with baselineMild post-inflammatory hyperpigmentation in one patient after 8-week treatment and mild acne in another patient after 4 weeks of treatment[@bb0240]\
\
Open-label, multicenter, prospective study26 ♀ with abdominal pregnancy-related striaeNot reported0.1% tretinoin cream daily for 3 mos applied to SG▪At treatment conclusion, global improvement was achieved from baseline in all stretch marks▪Pre-selected target lesion decreased in length by 20% and width by 23%Erythema and scaling were the most common adverse events[@bb0235]\
\
Double-blind placebo controlled study11 non-pregnant ♀ who had SG, 6 received treatment and 5 placeboNot reported0.025% tretinoin cream applied daily for 7 mos▪No statistically significant difference in treated group compared to control groupDid not assess[@bb0125]\
\
Double-blind, randomized, vehicle-controlled study22 healthy white ♀ with erythematous stretch marks, 10 received treatment and 12 vehicleStriae rubra0.1% tretinoin (n = 10) or vehicle (n = 12) daily for 6 mos to the affected areas▪At 2 mos, tretinoin patients had significant improvements in severity scores of SG vs. vehicle patients▪At 6 mos, 80% of tretinoin patients had improvement vs. 8% of vehicle patients▪Targeted stretch marks treated with tretinoin had decrease in mean length and width of 14% and 8%, respectively, vs. an increase of 10% and 24%, respectively, in vehicle patientsErythema and scaling, with itching and burning[@bb0020]\
\
Randomized controlled study10 American nonpregnant ♀ of varying skin types, age 23 to 49 yr.\
Striae age ranged from 8 mos to 31 yr and all were white striae.\
All patients had abdominal striae, 50% also had striae on thighsStriae alba20% glycolic acid + 0.05% tretinoin vs. 20% glycolic acid + 10% ascorbic acid, applied daily to abdomen or thighs for 12 weeks (each regimen was applied to half the treatment area)▪At treatment conclusion, 47% improvement with 0.05% tretinoin vs. 43% improvement with ascorbic acid▪Results not statistically significant from each other, but significant for both compared to pretreatment▪0.05% tretinoin increased elastin content at sites vs. untreated striae by 22% in the papillary and reticular dermis combined▪10% L-ascorbic acid failed to improve elastin content in either the papillary or reticular dermis▪Both regimens increased epidermal thickness and decreased papillary dermal thickness70% of patients experienced mild irritation at treatment initiation on both treatment sites.\
A single patient developed a mild irritant dermatitis[^5][^6]

Results {#s0015}
=======

Risk factors {#s0020}
------------

The most common risk factors for SG include younger age, maternal and family history of SG, higher pre-pregnancy and pre-delivery weight, and higher birth weight ([Table 1](#t0005){ref-type="table"}). Most studies showed a statistically significant association between these risk factors and SG, although [@bb0085] and [@bb0040] did not confirm pre-pregnancy weight or maternal age as a risk factor. Most studies also demonstrated that a history of striae on the breasts, hips, and thighs was associated with formation of SG; however, a study of 299 Caucasian women showed that although striae on the breasts increased risk of SG, striae on the thighs decreased the risk of SG. The study by [@bb0040] found a higher prevalence of SG in non-white women. With regard to socioeconomic status, multiple studies showed that unemployment, receiving state medical assistance, and lower education level were also associated with SG. However, confounding factors should be considered. Increased alcohol intake, decreased water consumption, decreased blood vitamin C levels, and expecting a male baby were also found to be more common among those women who developed SG in select studies. Even though it has been speculated that diabetes and increased serum glucose levels could play a part in the pathogenesis of SG, the studies included here did not reveal an association with diabetes or glycosylated hemoglobin levels. Studies were limited by study type, size, and patient population.

Prevention {#s0025}
----------

Preventative treatments have met with limited success. Creams that contain *Centella asiatica* extract, especially *Trofolastin* cream, are best supported by data for the prevention or reduction of the severity of SG ([Table 2](#t0010){ref-type="table"}; [@bb0100], [@bb0170]). *Centella asiatica* is a medicinal herb that is thought to increase the production of collagen and elastic fibers ([@bb0100]). [@bb0170] demonstrated that *Trofolastin* cream with *Centella asiatica* extract, α-tocopherol, and collagen--elastin hydrolysates that is applied daily from gestational week 12 until delivery significantly reduced the incidence of SG compared with placebo. Both [@bb0170] and [@bb0100] found that creams that contained *Centella asiatica* significantly reduced the intensity and/or severity of SG among women who did develop SG. [@bb0100] also demonstrated that the severity of previous striae significantly increased in the patient group treated with placebo but did not change in the patient group treated with *Centella* cream.

The application of almond oil, olive oil, or cocoa butter consistently failed to significantly lower the incidence of SG compared with placebo group. Two studies did find that when olive oil or almond oil were applied with a massage daily, they were associated with a lower incidence of SG development. However, these results may reflect the benefits of massage alone ([@bb0055], [@bb0305]).

Alphastria cream and verum cream, two proprietary creams that contain hyaluronic acid combined with various vitamins and fatty acids, were shown to significantly lower the incidence of SG in two studies ([@bb0065], [@bb0335]). Hyaluronic acid, the active ingredient in both creams, is thought to increase resistance to mechanical forces and oppose atrophy through stimulation of fibroblast activity and collagen production ([@bb0075], [@bb0135]). In both studies, the creams were applied through massage during the second trimester, which poses the question of whether the creams were truly beneficial or whether the results reflected the benefits of massage alone.

Management {#s0030}
----------

Although many studies that utilize topical medications or lasers for the treatment of nongestational SD have been performed, only a limited number of these studies focused specifically on SG treatment. Treatment should be instituted during the early stages of SG rather than when striae have matured and permanent changes have occurred. Many homeopathic and alternative therapies, including fruit and vegetable oils that hydrate the skin, are employed but limited by insufficient evidence.

### Topical medications {#s0035}

Tretinoin cream and a combination of 20% glycolic acid + 10% ascorbic acid were shown to improve SG in clinical studies ([Table 3](#t0015){ref-type="table"}). Use of tretinoin 0.05% and 0.1% creams on a daily basis for 3 to 7 months consistently resulted in overall global improvement of SG up to 47% ([@bb0020]), and decreased in mean length and width up to 20% and 23% respectively ([@bb0240]), of lesions. A study by [@bb0235] showed that the minimum effective concentration of tretinoin cream is 0.05%. Twenty percent glycolic acid combined with either 10% ascorbic acid or 0.05% tretinoin improved the appearance of SG although there was no statistically significant difference between the two combinations ([@bb0020]). Tretinoin increased elastin content in the papillary and reticular dermis of the lesions but ascorbic acid and untreated areas did not show such improvement. Both treatments increased epidermal thickness and decreased papillary dermal thickness in SG lesions.

### Laser treatments {#s0040}

A 1540-nm non-ablative fractional laser demonstrated a statistically-significant clinical improvement in SG that ranged from 1 to 24% and an observable difference at 3 months post-treatment ([@bb0165]). For nongestational SD, both fractional and non-fractional lasers have been employed with varying efficacies.

Among fractional lasers, both non-ablative Erbium (Er):Glass and ablative carbon dioxide (CO~2~) lasers have been studied. An average of 50 to 75% improvement in lesions after 2 to 6 nonablative Er:Glass treatments has been reported ([@bb0030], [@bb0060], [@bb0315]). Histologic studies showed an increase in elastic fibers and collagen production. This laser was generally safe and treatments were well-tolerated by patients. In a study by [@bb0140], ablative CO~2~ lasers were demonstrated to have improvements of 50 to 75%, especially in striae alba. However, other studies have shown inconsistent results ([@bb0045]). CO~2~ lasers are more painful and may have longer recovery times than non-ablative lasers.

Among non-fractional lasers, excimer, pulsed dye, neodymium-doped yttrium aluminum garnet (Nd:YAG), copper bromide, and diode have been studied in the treatment of patients with nongestational SD. The excimer 308-nm laser is used to treat mature striae alba by producing repigmentation and has achieved up to 75% increase in pigmentation; however, results are generally temporary and pigmentation of the normal surrounding skin is an unfavorable consequence ([@bb0110]). Pulsed dye laser results in textural improvements but has shown a limited benefit to treat striae alba ([@bb0180]). It may be beneficial in striae rubra by reducing erythema ([@bb0010]). Nd:YAG laser, also a vascular laser, demonstrated excellent improvement of up to 70% or more, even though it is specifically for immature striae rubra ([@bb0115]). Thirteen of 15 women experienced a complete resolution or modest improvement of striae for up to 2 years in a small study that used copper bromide laser ([@bb0145]). The diode laser was used to treat SD in dark-skinned individuals but this laser was ineffective and 64% of patients developed undesirable hyperpigmentation ([@bb0295]).

### Light treatments {#s0045}

Light therapy modalities such as intense pulsed light (IPL), ultraviolet (UV) light, and infrared light have been employed for the treatment of nongestational SD. IPL seems to result in at least moderate improvement of striae ([@bb0015]), but persistent erythema and post-inflammatory hyperpigmentation may complicate this treatment. UV light, especially a combination of UV-B and UV-A, has been shown to consistently repigment striae alba. However, the results are not permanent and maintenance treatment is required ([@bb0255]). Infrared light at 800 to 1800 nm can result in 25 to 50% improvement in striae alba after only four treatment sessions ([@bb0310]). Long-term studies with larger sample sizes are needed to confirm these results.

### Other modalities {#s0050}

Bipolar radiofrequency demonstrated clinical and histologic improvements in SD ([@bb0185]), while tripolar third generation radiofrequency (Tripollar) resulted in 25 to 75% improvement at 1 week post-final treatment ([@bb0175]). Modalities such as microdermabrasion and microneedling have been found to be effective to improve nongestational striae in multiple studies. Microdermabrasion has been especially effective for striae rubra ([@bb0005]). Microdermabrasion involves the blowing and subsequent vacuuming of abrasive substances to a treated area. Another study found that although microdermabrasion with sonophoresis improved striae, needling therapy yielded an even greater, statistically-significant improvement in striae compared with microdermabrasion ([@bb0190]). Needling therapy causes controlled skin injury with the goal of producing new collagen and elastin in the papillary dermis.

Discussion {#s0055}
==========

Stretch marks of pregnancy, which most commonly occur on the abdomen, breasts, hips, and thighs, have notably been a cause of distress and concern for the patient. Although many attempts have been made to identify risk factors, prevention methods, and treatments, a limited number of well-conducted, randomized controlled studies exist to date. This systematic review found that more studies addressed risk factors and prevention methods for SG than they did treatments specifically for SG and many more studies evaluated treatments for nongestational SD.

The most significant risk factors identified in this review are younger age, maternal and family history of SG, increased pre-pregnancy and pre-delivery weight, and increased birth weight. For prevention of SG, creams with *Centella asiatica* extract such as Trofolastin cream and a daily massage seem the most supported treatment options by the literature, but further studies are necessary. This information can be helpful for future expectant mothers who would like to try preventative treatments for SG. With regard to the management of SG, the current most effective therapies include tretinoin cream ≥ 0.05% and modalities such as nonablative fractional lasers. Laser treatment appears to yield on average greater mean improvement and in a much shorter time than topical treatments, but no head-to-head studies have been conducted to date. Tretinoin cream and laser treatments resulted in increased elastin content and collagen production in the treated lesions, which can partly explain the improvement observed. Many new studies that test novel laser treatments, microdermabrasion, and microneedling are underway.

Study limitations may explain the conflicting results in some studies. For example, some studies observed pre-pregnancy weight as a significant risk factor ([@bb0220]), but other studies did not view this but rather a genetic component as the most significant risk factor ([@bb0040]). The available studies often include a small and non-randomized sample size, especially those studies that are relevant to treatment. Additionally, studies do not always indicate the types of striae that are treated. Many more studies have been conducted for nongestational SD, which brings up the concern of whether these results may be extrapolated to SG.

SG are commonly regarded as a cosmetic nuisance and overlooked by practitioners as clinically insignificant. Skindex-29 is a validated questionnaire on the quality of life of patients with dermatologic conditions that has been used to assess total impairment caused by SG. The questionnaire focuses on three scales: emotion (psychological effects), symptoms, and daily functioning. In a study by [@bb0340] to evaluate the quality of life of women with SG through the Skindex-29 questionnaire, the authors observed significantly greater psychological and/or emotional impairment among pregnant women with SG compared with women without SG ([@bb0340]). Using the same questionnaire, they also noted that pregnant women with severe SG scored significantly higher in areas of psychological and/or emotional impairment as well as daily functioning impairment, compared with those without SG and those with mild SG.

Conclusion {#s0060}
==========

Striae gravidarum are a common form of gestational change that can be a substantial source of distress. Despite the identification of risk factors, prevention of SG remains challenging. Various therapies have been used to improve the appearance of SG. Fractional lasers and topical medications have yielded promising results. Further results from large, randomized-controlled studies are required to validate prevention and treatment options and their long-term efficacy data.
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